Acumen Pharmaceuticals, Inc. (ABOS) Reports In-Line Q2 EPS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/2/2026
- S&P 500 ends down; Apple dips ahead of quarterly report
- Apple beats quarterly estimates for profit and revenue
- Marvell agrees $115 billion all-stock deal to buy Lumentum
- Oil drops 7% as Iran signals openness to peace talks
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mailGet Alerts ABOS Hot Sheet
Join SI Premium – FREE
Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) reported Q2 EPS of ($0.25), in-line with the analyst estimate of ($0.25).
For earnings history and earnings-related data on Acumen Pharmaceuticals, Inc. (ABOS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Apple (AAPL) Tops Q4 EPS by 11c, Beats on Revenue, Beats on iPhone sales, Misses China
- Waystar Holding Corp. (WAY) Reports Q3 EPS of $0.44
- Hinge Health, Inc. (HNGE) Tops Q3 EPS by 6c, raises Guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
